Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

This study has been completed.
Sponsor:
Information provided by:
Orexigen Therapeutics, Inc
ClinicalTrials.gov Identifier:
NCT00364871
First received: August 14, 2006
Last updated: April 18, 2008
Last verified: April 2008
  Purpose

The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.


Condition Intervention Phase
Obesity
Drug: naltrexone and bupropion SR
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study of Combination Therapy for Safety and Efficacy in Subjects With Uncomplicated Obesity

Resource links provided by NLM:


Further study details as provided by Orexigen Therapeutics, Inc:

Primary Outcome Measures:
  • Percentage change in total body weight [ Time Frame: baseline to week 24 ] [ Designated as safety issue: No ]

Enrollment: 410
Study Start Date: April 2005
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Experimental: 2
Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Active Comparator: 3
Bupropion SR (400 mg/day)
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Active Comparator: 4
Naltrexone (48 mg/day)
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Placebo Comparator: 5
B-Placebo plus N-Placebo
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Placebo Comparator: 6
B-Placebo plus N-Placebo
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
Experimental: 7
Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
Drug: naltrexone and bupropion SR
naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day

Detailed Description:

A completed proof of concept study, OT-101 (Data on File, Orexigen Therapeutics, 2005), demonstrated that a combination of 300 mg bupropion SR and 50 mg naltrexone was associated with greater weight loss than bupropion SR alone, naltrexone alone, or placebo in subjects with uncomplicated obesity.

The hypothesis for the current trial is that by adjusting the doses and titration schedules of bupropion SR and naltrexone greater efficacy and improved tolerability can be achieved. In this trial, a higher dose of bupropion and 2 lower doses of naltrexone than utilized in the previous trial (OT-101) will be evaluated. The doses of both drugs will be titrated over 4 weeks and administered twice a day. There are 2 cohorts. At each site, cohort 2 recruitment began as soon as cohort 1 enrollment was completed. Cohort 1 treatment groups are (60 per group):

  • Group 1: Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
  • Group 2: Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
  • Group 3: Bupropion SR (400 mg/day) plus N-Placebo
  • Group 4: B-placebo plus Naltrexone (48 mg/day)
  • Group 5: B-Placebo plus N-Placebo

Cohort treatment 2 Groups are:

  • Group 6: B-Placebo plus N-Placebo (n=20)
  • Group 7: Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)(n=60)
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male subjects, 18 to 60 years of age
  • Have body mass index (BMI) of 30 to 40 kg/m2
  • Free from clinically significant illness or disease as determined by medical history and physical examination
  • Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to baseline
  • Normotensive (systolic <140 mm Hg; diastolic <90 mm Hg). Anti-hypertensive medications are allowed with the exception of adrenergic blockers, beta-blockers and clonidine. Medical regimen must be stable for at least 6 weeks
  • LDL cholesterol < 190 mg/dL and triglycerides < 400 mg/dL. Medications for treatment of dyslipidemia are allowed as long as medical regimen has been stable for at least 6 weeks
  • No clinically significant abnormality of serum albumin, blood urea nitrogen, creatinine, calcium and phosphorus
  • Bilirubin, ALT and AST within 1.5 x ULN
  • No clinically significant abnormality of hematocrit, white blood cell count, white cell differential, or platelets
  • Fasting glucose less than 140 mg/dL on no hypoglycemic agents
  • No clinically significant abnormality on urinalysis
  • TSH within 1.5 x ULN, normal T3, if TSH below lower limit of normal
  • Negative serum pregnancy test in women with intact uterus
  • Score < 11 for depression and score < 11 for anxiety on Hospital Anxiety and Depression (HAD) Scale
  • ECG: no clinically significant abnormality
  • Score of zero on the Mood Assessment questionnaire and a response of "No" to the Bipolar Disorder Questions
  • If female with child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drugs
  • Able to comply with all required study procedures and schedule
  • Willing and able to give written informed consent

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome)
  • Serious medical condition or medical condition that limits participation in the prescribed exercise program: (e.g. unstable cardiovascular disease including congestive heart failure, angina pectoris, and myocardial infarction; stroke; claudication; acute limb ischemia; acute renal or hepatic disorder; renal, hepatic or respiratory insufficiency)
  • Active malignancy or history of malignancy (other than non-melanoma skin cancer or surgically cured cervical cancer) within 5 years of enrollment
  • Serious psychiatric condition (e.g., any history of bipolar disorder, psychosis, suicidal attempt or post-partum depression; a history of major depression, suicidal ideation or antidepressant use within 1 year)
  • Type I or Type II diabetes mellitus requiring pharmacotherapy
  • Excluded concomitant medications: anorectic agents; weight loss agents; dietary supplements to promote muscle building, enhance mood, or reduce appetite; adrenergic blockers; beta blockers; anti-psychotic agents; clonidine; theophylline; cimetidine; oral corticosteroids; anti-depressant; topiramate; Depo-Provera®, smoking cessation agents; frequent, known use of opioid or opioid-like analgesics
  • History of surgical intervention for obesity
  • History of seizure disorder or predisposition to seizures (e.g., history of cerebrovascular accident, significant head trauma, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • History of bulimia or anorexia nervosa
  • History of drug or alcohol abuse within 5 years
  • History of treatment with bupropion, or naltrexone within 12 months
  • History of hypersensitivity to bupropion, or naltrexone
  • Use of drugs, herbs, or dietary supplements known to significantly affect body weight within one month of baseline
  • Use of investigational drug, device or procedure within 90 days
  • Participation in any previous clinical trial conducted by Orexigen Therapeutics
  • Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00364871

Locations
United States, California
Scripps Clinic Del mar
San Diego, California, United States, 92130
United States, Georgia
CSRA Partners in Health, Inc
Augusta, Georgia, United States, 30909
United States, Kentucky
UK Clinical Research Organization
Lexington, Kentucky, United States, 40536
United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808
United States, North Carolina
Center for Nutrition and Preventive Medicine
Charlotte, North Carolina, United States, 28211
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, South Carolina
MUSC Weight Management Center
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Orexigen Therapeutics, Inc
Investigators
Principal Investigator: Frank Greenway, MD Pennington Biomedical Research Center
  More Information

No publications provided

Responsible Party: Eduardo Dunayevich, MD, Orexigen Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT00364871     History of Changes
Other Study ID Numbers: NB201
Study First Received: August 14, 2006
Last Updated: April 18, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Orexigen Therapeutics, Inc:
Obesity

Additional relevant MeSH terms:
Obesity
Body Weight
Nutrition Disorders
Overnutrition
Overweight
Signs and Symptoms
Bupropion
Naltrexone
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Narcotic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014